Donald F. Weaver
RSC Med. Chem., 2023,14, 1645-1661
Abstract
Decades of research have yet to identify a disease modifying drug for Alzheimer's disease. This review provides an evaluation of the leading twelve druggable targets (microglial and cytokine), addressing the role of neuroinflammation in Alzheimer's.
Yaojun Ju, Yichen Yan, Xinhui Wang, Shan Li, Jialei Wang, Zixiao Wang, Yuling Dong and Junping Wang
Food Funct., 2025,16, 9519-9532
Abstract
This study investigated the therapeutic potential and mechanisms of Acer truncatum Bunge seed oil (ATSO) against cuprizone-induced white matter injury and cognitive decline.
R. S. K. Vijayan, Matthew M. Hamilton, Dana E. Pfaffinger, Fernando G. Alvarez, Naphtali J. Reyna, Jennifer P. Bardenhagen, Hannah Shepard, Christian Rodriguez, Sunil Goodwani, Yaima Lightfoot, Klaus Maskos, Sven Johannsson, Georg Kempf, Quanyun Alan Xu, Lars Neumann, Yongying Jiang, Mary Geck Do, Philip Jones, Richard T. Lewis, William J. Ray and Jason B. Cross
RSC Med. Chem., 2025,16, 5341-5358
From themed collection:
Kinases
Abstract
Parallel virtual screening and structure-guided optimization enable discovery of novel allosteric RIPK1 inhibitors.
Chuan Hu, Baoyu Wu, Yihan Wu, Mingyi Shi, Jiaqi Ma, Huile Gao and Jinming Zhang
Mater. Chem. Front., 2023,7, 5171-5186
From themed collection:
2023 Materials Chemistry Frontiers HOT articles
Abstract
This review provides an overview of recent advances in nanotechnology that are achieved to improve the therapeutic efficiency for treating Alzheimer's disease.
Ji-xiang Liu, Ri-song Na, Lian-juan Yang, Xu-ri Huang and Xi Zhao
Phys. Chem. Chem. Phys., 2023,25, 31418-31430
Abstract
Six small molecules from virtual screening hits may treat neurodegenerative diseases and SARS-CoV-2 by inhibiting RIPK1.